Novel Alpha-Glucan Metabolism

This study will be randomized, double blind, placebo-controlled, single-center, and 3x3 crossover in design. Eligible participants will be randomized to receive the below products in single dose and in different random sequence, as determined by the randomization system

• 50 g novel alpha glucan
• 50 g (rapidly digestible control)
• 15 g (dietary fiber)

Inclusion criteria

Healthy status (based on anamnesis) Body mass index (BMI) between 18.5 and 29.9 kg/m2 Able to understand and sign informed consent form.

Exclusion criteria

• Pregnant or lactating women
• Type I and type 2 diabetes
• Known food allergy or intolerance to test product
• Major medical/surgical event in the last 3 months potentially interfering with study procedures and assessments
• Abnormal bowel transit, history of a gastrointestinal disorder (e.g., inflammatory bowel disease, diverticular diseases, colon cancer), or history of chronic constipation with passage of fewer than 3 spontaneous bowel movements per week on average or chronic or recurrent diarrhea with spontaneous bowel movements more often than 3 times daily
• Any concomitant medication potentially interfering with study procedures and assessment: such as antibiotics, antiacids, or other medications impacting transit time, colonoscopy, irrigoscopy or other bowel cleansing procedures four weeks prior the test
• Recent episode of an acute gastrointestinal illness
• Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer.
• Smokers
• Volunteer who cannot be expected to comply with the protocol
• Family or hierarchical relationships with Clinical Innovation Lab team